US Gives Merck’s Antitoxin Priority Review

The US Food and Drug Administration (FDA) has granted priority review to US drug maker Merck & Co for bezlotoxumab, an antitoxin for preventing the recurrence of Clostridium difficile (C. difficile) infection. The agency has given a Prescription Drug User Fee Act action date of Jul. 23, 2016.

Merck’s Biologics License Application was partly based on data from Phase I and II clinical trials. Bezlotoxumab is designed to neutralize C. difficile toxin B which can damage the bowel wall and cause inflammation, leading to diarrhea.

Roy Baynes, senior vice president of clinical development at Merck Research Laboratories, said recurrence of C. difficile infection is one of the most common healthcare-associated infections in US hospitals. Currently, here are no approved therapies available.

The European Medicines Agency is also reviewing the antitoxin.

Separately, following a priority review, the FDA has approved Merck’s Zepatier for treating adults with chronic hepatitis C genotype (GT) 1 or GT4 infection, with or without ribavirin.

In multiple clinical studies, Zepatier is said to have achieved high rates of sustained virologic response in the range 94-97% in GT1-infected patients and 97-100% in GT4-infected patients.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.